Oct 29 (Reuters) - DaVita ( DVA ) missed Wall Street

estimates for third-quarter profit on Wednesday, as the kidney

dialysis provider grappled with rising patient care costs and

declining treatment volumes.

The Colorado-based company, which offers dialysis services

through outpatient clinics and at-home care across the United

States, said average daily U.S. dialysis treatments fell 0.5%

from the previous quarter to 91,680. Compared with a year

earlier, normalized non-acquired treatment growth declined 0.6%.

Patient care costs per treatment rose nearly 6%

year-over-year to $271.23 for the nine-month period, driven by

pharmaceutical and compensation costs.

General and administrative expenses also rose to $322

million in the quarter, up $10 million from the prior quarter,

primarily due to IT-related costs.

DaVita ( DVA ) is still dealing with the fallout from a ransomware

attack in April that disrupted parts of its operations and

exposed the personal data of 2.7 million people.

The company incurred $11.7 million in costs during the

quarter to remediate the incident and restore systems, it said.

For the quarter ended September 30, DaVita ( DVA ) reported adjusted

profit of $2.51 per share, below analysts' average estimate of

$3.23, according to LSEG data.

Revenue came in at $3.42 billion, just shy of expectations

of $3.43 billion.

The company raised the lower end of its full-year profit

forecast. The company now expects 2025 adjusted per-share profit

between $10.35 and $11.15, compared with its previous

expectation of $10.20 to $11.30.

Shares of the company were down about 2% in extended

trading.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil

D'Silva)